

APR 16 2002  
PATENT & TRADEMARK OFFICE

1642

AMENDMENT TRANSMITTAL LETTER			DOCKET NUMBER: P-LJ 4575		
SERIAL NO: 09/765,086	FILING DATE: Jan. 17, 2001	EXAMINER: M. Yu	GROUP ART UNIT: 1642		
INVENTION: CHIMERIC PROSTATE-HOMING PEPTIDES WITH PRO-APOPTOTIC ACTIVITY					

TECH CENTER 1600/2900

APR 19 2002

RECEIVED

TO COMMISSIONER FOR PATENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on April 8, 2002.

By: Andrea L. Gashler  
Andrea L. Gashler, Reg. No. 41, 029

April 8, 2002  
Date of Signature

Transmitted herewith is a Response to Restriction Requirement mailed March 26, 2002, in the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27.
- ☐ Petition for Extension of Time is enclosed (in duplicate).
- ☒ No additional claims fee is required.
- ☐ An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE			FEE	
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	22	-	22	-	0	x	\$9	\$18	=	\$0	\$
INDEPENDENT CLAIMS	1	-	0	-	0	x	\$42	\$84	=	\$0	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			<input type="checkbox"/> YES		<input checked="" type="checkbox"/> NO		\$140	\$280	=	\$0	\$
TOTAL ADDITIONAL FEE										\$0	\$

\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

\*\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

\*\*\* If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

☐ Please charge my Deposit Account No. 03-0370 the amount of \$\_\_\_\_\_. A duplicate copy of this sheet is enclosed.

☐ A check in the amount of \$\_\_\_\_\_ is enclosed, \$\_\_\_\_\_ of which covers the fee for a \_\_\_\_\_-month extension of time.

Inventors: Ruoslahti et al.  
Serial No.: 09/765,086  
Filed: January 17, 2001  
Page 2

- X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- X Any additional filing fees required under 37 C.F.R. 1.16.
- X Any patent application processing fees under 37 C.F.R. 1.17.
- X The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Andrea L. Gashler  
Andrea L. Gashler  
Registration No. 41,209  
CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive  
7<sup>th</sup> Floor  
San Diego, California 92122  
858-535-9001  
USPTO CUSTOMER NO. 23601



PATENT

Our Docket: P-LJ 4575

TECH CENTER 1600/2900

APR 19 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
Ruoslahti et al.

Serial No.: 09/765,086

Filed: January 17, 2001

For: CHIMERIC PROSTATE-HOMING  
PEPTIDES WITH PRO-APOPTOTIC  
ACTIVITY

Commissioner for Patents  
Washington, D.C. 20231

)  
) Examiner: M. Yu

)  
) Group Art Unit: 1642

) I hereby certify that this correspondence  
) is being deposited with the United States  
) Postal Service as first class mail in an  
) envelope addressed to: Commissioner for  
) Patents, Washington, D.C., 20231, on  
) April 8, 2002.

By Andrea L. Gashler  
Andrea L. Gashler, Reg. No. 41,029

April 8, 2002  
Date of Signature

RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the Office Action mailed March 26, 2002,  
consideration of the following remarks respectfully is requested.

I. REMARKS

Claims 1 to 22 are pending. The Examiner alleges that  
the claims are directed to two distinct and independent  
inventions as follows:

Group I: Claims 1 to 7, drawn to chimeric  
peptides; and

Group II: Claims 8 to 22, drawn to methods of  
directing an antimicrobial peptide to a  
prostate cancer *in vivo*.